Cetuxa, the world’s first biosimilar of Cetuximab used for the treatment of head and neck cancer. This is in line with the company’s endeavour to ensure afo dability, accessibility, and availability while saving the lives of critically ill Cancer patients. Cetuxa has been researched an

Cetuxa has been researched and manufactured indigenously by Enzene Biosciences Limited, the biological arm of Alkem Laboratories....Cetuxa is administered as an intravenous infusion and is available as 100 mg (2 mg/mL) in a single-dose vial. Initial dose is 400 mg/m2, follow-up of 250 mg/m2 per week."

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] . Cetuximab is a chimeric (mouse/human) …

On May 26, 2023, the European Commission granted the marketing authorization to Samsung Bioepis for EPYSQLI, a biosimilar referencing SOLIRIS (eculizumab) developed by Alexion for the treatment of the paroxysmal nocturnal hemoglobinuria (PNH) that had global sales of approximately $5 trillion last year.

2023年5月30日 · Alkem Oncology introduces Cetuxa, the world’s first biosimilar of Cetuximab, for head and neck cancer treatment. Cetuxa aims to enhance accessibility and affordability for critically ill cancer patients.

2023年6月15日 · Alkem Oncology has launched Cetuxa, the world’s first biosimilar of Cetuximab used for the treatment of head and neck cancer. Cetuxa has been researched and …

2024年1月19日 · 西妥昔单抗是一种对抗 表皮生长因子受体 （EGFR）的单克隆抗体，经美国食品药物管理局核可使用于治疗转移型结肠直肠癌和头颈癌。 西妥昔单抗是靶向药,抑制肿瘤细胞分泌的血管生长因子，减少肿瘤血管的新生和转移。 研究显示有些结肠直肠癌病患的癌细胞会表现大量的表皮生长因子受体，可能是造成细胞癌化的原因之一，西妥昔单抗是针对癌细胞的这项特色发展出来的标靶药物，就可以专一地抑制癌细胞的生长，减少对其他正常细胞的影响，因此可以减 …

2023年5月30日 · Alkem Oncology has launched Cetuxa, a biosimilar version of Cetuximab used in the treatment of head and neck cancer. Cetuximab is a Merck drug sold under the brandname Erbitux. Alkem’s Cetuxa...

西妥昔单抗是一种单克隆抗体，能特异性结合表皮生长因子受体（EGFR），并竞争性抑制EGF及其它配体（如转化生长因子α）与该受体结合，进而阻断细胞内信号转导途径，从而抑制癌细胞的增殖，诱导癌细胞的凋亡，减少基质金属蛋白酶和血管内皮生长因子（VEGF）的产生。 2022年6月16日，德国默克（Merck KGaA）宣布，其抗肿瘤新药西妥昔单抗注射液（商品名：爱必妥）获得中国国家药品监督管理局（NMPA）批准，与放疗联合用于治疗局部晚期头颈部鳞状细胞 …

2024年9月30日 · Cetuximab is used in the treatment of head and neck cancer and cancer of colon and rectum. Cetuximab is a monoclonal antibody that specifically binds to receptors on cancer cells. Thus it flags the cancer cells for destruction by the body's immune system.